ST034307

ST034307 is a potent and selective adenylyl cyclase 1 (AC1) inhibitor, with IC₅₀ of 2.3 μM. IC50 & Target: IC50: 2.3 μM (AC1)^[1] In Vitro: ST034307 reveals selective inhibition of AC1 and potentiates AC8 activity to a nonsignificant small extent. ST034307 potentiates phorbol 12-myristate 13-acetate (PMA)-stimulated cAMP production by AC2. ST034307 significantly inhibits the forskolin- or isoproterenol-stimulated AC1 activity in HEK cells stably expressing AC1. In contrast, ST034307 has no significant effects in the wild-type HEK cells. ST034307 significantly inhibits the Ca²⁺/calmodulin-stimulated cAMP accumulation in the hippocampal homogenates. ST034307 dose-dependently inhibits both the development and the maintenance of MOR-mediated sensitization of AC1^[1]. In Vivo: ST034307 (0.25 μg) causes a significant relief of CFA-induced inflammatory pain in mice. ST034307 exhibits an estimated median effective dose (E₅₀) value for analgesia of 0.28 μg in the mouse pain model^[1].